26 Nov 2009 07:00
26 November 2009
Source BioScience plc
('Source BioScience' or 'the Company')
Source BioScience to offer Fluidigm SNP genotyping service
Source BioScience plc (LSE: SBS), the provider of expert, quality services to the healthcare, pharma biotech and life science research sector, is pleased to announce the addition of the Fluidigm EP1™ System, a microfluidic-based single nucleotide polymorphism ('SNP') genotyping platform, to its portfolio of life science services.
Source BioScience announced the new service at the launch of the University College London ('UCL') Genetics Institute ('UGI') and the service will be offered from the Company's DNA sequencing and genotyping facility located at UCL.
HIGHLIGHTS
The introduction of the Fluidigm-based SNP genotyping service is a key component in the Company's portfolio of genomic service provision to the life science research sector
The technology will attract new customers and will also enable Source BioScience to satisfy all the genotyping requirements of existing customers
Source BioScience continues to leverage its expertise in genomic analyses and laboratory services for the increased penetration of its molecular biology services into the UK life science research sector
Fluidigm Corporation of San Francisco, USA, develops, manufactures and markets proprietary systems that significantly improve productivity in life science research and related activities including molecular diagnostics and personalised medicine. The Fluidigm genotyping technology uses established, robust chemistry, facilitating thousands of experiments at a time, in a fully flexible format that maximises sensitivity, reduces costs and provides excellent reproducibility of results.
Nick Ash, Managing Director of Source BioScience said: "Source BioScience is delighted to be working with Fluidigm as the first commercial service provider of this platform in the UK. The technology offers our customers a flexible and cost effective solution to their genotyping needs. This represents a key component in our genotyping service provision, completing our portfolio and enabling us to provide a full range of genotyping services."
Sharon Alldrick, UK Sales Manager for Fluidigm added: "We are very excited about working with Source BioScience to launch the Fluidigm genotyping service in the UK. The demand for Fluidigm service provision is very strong, and increasing, in the UK and across Europe. Source BioScience has considerable expertise in genotyping services and is now equipped with the technology to meet the demand for this important customer segment."
-- ENDS --
For further information, please contact:
Source BioScience plc Dr Nick Ash Managing Director Tel: +44 (0) 115 973 9010 www.sourcebioscience.com
Fluidigm Sharon Alldrick UK Sales ManagerTel: +44 (0) 7825 335730 www.fluidigm.com
Bishopsgate Communications Nick Rome / Gemma O'Hara Tel: + 44 (0) 207 562 3350 www.bishopsgatecommunications.com
About Source BioScience:
Source BioScience (LSE: SBS) is a highly focused healthcare and biotechnology company providing diagnostic and screening services to the healthcare community and genetic analyses and biomolecular tools and products to the life science research and pharma biotech sectors.
Its Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases and additional predictive testing for treatment optimisation for clinicians and patients. Pharma Biotech Services offers support for early stage therapeutic development, offering a 'one-stop shop' from tissue pathology, immunohistochemistry, sophisticated image analysis, biomarker determination and assay development to pharmacogenomics including genotyping and gene expression analysis. Life Science Research services provide core laboratory research support from conceptualization to implementation, calling upon a wide range of cutting-edge technology platforms including an online catalogue of biomolecular tools. This incorporates DNA sequencing, whole genome amplification and a comprehensive library of genomic reagents and clones including cDNA and RNAi, as well as facilitating rapid access to high quality antibodies, cell cultures, diagnostic assays for cancer and other genetic testing, and related research tools.
The Group has its headquarters in Nottingham, UK where it operates state of the art reference laboratory facilities, with additional UK laboratory facilities in London, Cambridge and Oxford. Source BioScience is CPA, GLP and GCP accredited and is licensed by the Human Tissue Authority.
Further information about Source BioScience can be found at www.sourcebioscience.com
About Fluidigm:
Fluidigm develops, manufactures and markets proprietary Integrated Fluidic Circuit (IFC) systems that significantly improve productivity in life science research. Fluidigm's IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These "integrated circuits for biology" are made possible by miniaturizing and integrating liquid handling components on a single microfluidic device (IFC). Fluidigm's systems, consisting of instrumentation, software and single-use chips, increase throughput, decrease costs and enhance sensitivity compared to conventional laboratory systems. Fluidigm products have not been cleared or approved by the Food and Drug Administration for use as a diagnostic and are only available for research use.
Further information about Fluidigm can be found at www.fluidigm.com